NICE slammed after recommending removal of drugs from CDF
A ‘huge blow to patients’ and the realization of ‘our worst fears' about the re-launched Cancer Drugs Fund (CDF), is how one charity has reacted to the recommended discontinuation of treatments in England.
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness watchdog for England and Wales, published draft guidance on Thursday which could lead to the removal of two medicines from the CDF, which was revamped last month.
The drugs concerned are breast cancer treatment everolimus, which is marketed by Swiss pharma giant Novartis (NOVN: VX) as Afinitor, and ibrutinib for mantle cell lymphoma, which is sold under the name Imbruvica by Janssen, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze